• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Abbott laboratories pakistan (pvt) limited
 

Abbott laboratories pakistan (pvt) limited

on

  • 1,260 views

Abbott Laboratories functions, operations and market share.

Abbott Laboratories functions, operations and market share.

Statistics

Views

Total Views
1,260
Views on SlideShare
1,260
Embed Views
0

Actions

Likes
1
Downloads
30
Comments
1

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

CC Attribution License

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel

11 of 1 previous next

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
  • why upload ??? if you don't have ability to share ?
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Abbott laboratories pakistan (pvt) limited Abbott laboratories pakistan (pvt) limited Presentation Transcript

    • Presented By :Syed Faraz RizviMBA-II(Karachi University)
    • IntroductionVision & Mission StatementCore ValuesProductsSWOT AnalysisAchievementsIndustry InfoCompetitorsMarket ShareFinancial Data
    • A Global Broad-Based Health Care Company.Founded in USA about 120 years ago.Operating In more than 130 Countries with over70,000 Employees.Business OperationsPharmaceuticalsNutritionalDiagnosticsDiabetes Care
    • Abbott Pakistan is a part of the GlobalHealth Care Corporation of AbbottLaboratories, Chicago, USA.Started operations in Pakistan in 1948.Along with 1500 Employees with 2Locations Abbott is discovering newMedicinesTechnologiesWaysTo manage „Health‟
    • “To be a premier healthcarecompany in Pakistan”
    • „A Promise for Life‟Turning Science into Caring
    • Pioneering Leading edge Science &CommercializationAchieving World-Class Execution.Caring Making a difference in people‟s lives.Enduring Commitment & purpose.
    • Manufacturing more than 160 productsA broad range Including Pharmaceutical Products General Health Care Products Nutritional Products Diagnostics Products Diabetes Care
    • Pharmaceuticals Products
    • General Health CareProducts
    • Nutritional Products
    • Diagnostics Products
    • Diabetes Care
    • Abbott acquired Knoll BASF Pharma in2000 for $6.9 billion.On June 2005 Abbott achieved class „A‟accreditation against Oliver Wight ABCDchecklist.
    • StrengthsGood company ReputationStrong Distribution NetworkStrong Brand positioningDeep roots in Pharma businessProfessional Management Team
    • WeaknessesComparatively High PricesRelying on Imported Raw MaterialLacking of deep rural penetration
    • OpportunitiesA part of high potential EconomyHigh rate of population increase inPakistanIncreasing Healthcare awareness
    • ThreatsHigh Inflation rateForeign exchange ratePolitical condition of PakistanGovt restriction on price
    • The Pakistan pharmaceutical industry meetsaround 70% of the country‟s demand offinished medicineWith an export turnover of over US $ 100million as of 2007.Market Share divided into 59% Local 41%multinational
    • 7.64.33.95.9012345678GSK Highnoon Labs Getz Pharma Abbott LabMarket ShareGSKHighnoon LabsGetz PharmaAbbott Lab59% Local 41% multinationalSOME MAJOR PLAYERS IN PHARMA INDUSTRY
    • 1st Qtr21%2nd Qtr43%3rd QtrAug,201036%4th Qtr0%Sales 2010YEAR PROFIT AFTER TAXATION(3rd Quarter)31 Aug-2010 Rs. 315,000,000(2nd Quarter & Half ended) May31st, 2010.Rs. 339,047,000(1st Quarter) February 28, 2010. Rs. 184,519,000
    • YEARS TOTAL SALES(Rs in 000)PROFIT Rs 000(after taxation)Net Profit toSales %2009 8,450,118 825,676 9.82008 7,123,412 343,980 4.82007 6,584,454 1,184,762 18.02006 5,914,181 1,000,008 16.99.80%4.80%18%16.90%0.00% 5.00% 10.00% 15.00% 20.00%2009200820072006Net Profit to SalesNet Profit to Sales %
    • 38.50%22.41%0.03%44.35%0.10%To EmployeesTo GovernmentTo SocietyTo Providers ofCapitalTo Providers ofFinance2009 Spendings2009
    • •No Doubt upon Company‟s ability toContinue as a going concern.•Assets Rs. 4.9 Billion(2009)•Cash in Hand only Rs. 770 Million(2009)